|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||22.97 - 22.97|
|52-week range||16.50 - 23.47|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||19.94|
|Forward dividend & yield||1.10 (5.15%)|
|Ex-dividend date||18 Nov 2021|
|1y target est||N/A|
In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.